Table of Contents

company-logo

Coeptis Therapeutics Holdings, Inc., a biopharmaceutical company, develops and commercializes generic and branded pharmaceutical products and cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a Vy-Gen drug product for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; and CD38-Diagnostic, an in vitro screening tool to provide the ability to pre-determine which cancer patients are most likely to benefit from targeted anti-CD38 monoclonal antibodies therapies. The company has collaboration with Statera BioPharma to develop and commercialize STAT-201 for Crohn's disease; and Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson's Disease. Coeptis Therapeutics Holdings, Inc. was founded in 2017 and is headquartered in Wexford, Pennsylvania.

Coeptis Therapeutics Dividend Announcement

• Coeptis Therapeutics does not currently offer dividends, we're keeping a close eye on its growth potential and financial developments.
• Stay tuned for updates on Coeptis Therapeutics dividend policy and future announcements. In the meantime, explore other dividend-yielding opportunities on our website.

Coeptis Therapeutics Dividend History

Coeptis Therapeutics Dividend Yield

Coeptis Therapeutics current trailing twelve-month (TTM) dividend yield is -%. Interested in purchasing Coeptis Therapeutics stock? Use our calculator to estimate your expected dividend yield:

Coeptis Therapeutics Financial Ratios

P/E ratio-0.07
PEG ratio0.01
P/B ratio0.17
ROE-225.59%
Payout ratio0.00%
Current ratio0.40
Quick ratio0.40
Cash Ratio0.33

Coeptis Therapeutics Dividend FAQ

Does Coeptis Therapeutics stock pay dividends?
Coeptis Therapeutics does not currently pay dividends to its shareholders.
Has Coeptis Therapeutics ever paid a dividend?
No, Coeptis Therapeutics has no a history of paying dividends to its shareholders. Coeptis Therapeutics is not known for its dividend payments.
Why doesn't Coeptis Therapeutics pay dividends?
There are several potential reasons why Coeptis Therapeutics would choose not to pay dividends to their shareholders:

1. Growth opportunities: Companies, especially in fast-growing industries like technology, reinvest earnings into expansion, R&D, or acquisitions to fuel future growth and increase company value.

2. Tax implications: Not paying dividends can reduce the tax burden on shareholders, who may prefer to defer taxes until selling shares and realizing capital gains.

3. Investor preferences: Some investors prefer companies to reinvest profits for higher long-term returns, particularly those seeking capital appreciation over income.

4. Capital allocation priorities: Companies may allocate cash to pay down debt, fund share buybacks, or invest in projects with higher returns than dividends.

5. Market expectations: In certain sectors, like technology, reinvesting profits for growth and innovation is often prioritized over distributing dividends to shareholders.
Will Coeptis Therapeutics ever pay a dividend?
The decision for a company to pay dividends depends on various factors including its financial performance, growth prospects, capital allocation priorities, and shareholder preferences. While Coeptis Therapeutics has not paid dividends historically and has instead focused on reinvesting its earnings for growth, it's ultimately up to the company's management and board of directors to decide whether to initiate a dividend policy in the future.
Is Coeptis Therapeutics a dividend aristocrat?
Coeptis Therapeutics is not considered a Dividend Aristocrat. The term "Dividend Aristocrat" is typically used to describe a company in the S&P 500 index that has increased its dividend payouts for at least 25 consecutive years.
Is Coeptis Therapeutics a dividend king?
Coeptis Therapeutics is not classified as a "Dividend King". A Dividend King is a company that has managed to increase its dividend payouts for 50 consecutive years or more, which is an even more selective group than the Dividend Aristocrats.
Is Coeptis Therapeutics a dividend stock?
No, Coeptis Therapeutics is not considered a dividend stock. A dividend stock is a stock of a company that regularly pays out dividends to its shareholders.
How to buy Coeptis Therapeutics stocks?
To buy Coeptis Therapeutics you need a brokerage account. Open an account with a reputable brokerage firm that offers access to the stock market. Consider factors such as fees and account minimums.

Place an order: Use the brokerage's trading platform to place an order to buy Coeptis Therapeutics stock.

Remember that buying stocks involves risk, and it's important to carefully consider your investment goals, risk tolerance, and conduct thorough research before making any investment decisions.